Regulation 221 Amendment of regulation 327 (powers of inspection, sampling and seizure)I1

United Kingdom

(1)

Regulation 327 M1 is amended as follows.

(2)

In paragraph (1)(c)—

(a)

in paragraph (v), insert “ UK ” before “marketing authorisation”;

F1(b)

after paragraph (v), insert—

“(va)
an EU marketing authorisation;”.

F2(3)

In paragraph (2)(g), after paragraph (iv) insert—

“(iva)
the requirements of Schedule 12A (further provision as to the performance of pharmacovigilance activities);”.

F3(4)

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

F4(5)

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Annotations

F1: Reg. 221(2)(b) substituted for reg. 221(2)(b)(c) (31.12.2020 immediately before IP completion day) by The Human Medicines (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1488), reg. 1, Sch. 2 para. 180(a)
F2: Reg. 221(3) substituted (31.12.2020 immediately before IP completion day) by The Human Medicines (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1488), reg. 1, Sch. 2 para. 180(b)
F3: Reg. 221(4) omitted (31.12.2020 immediately before IP completion day) by virtue of The Human Medicines (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1488), reg. 1, Sch. 2 para. 180(c)
F4: Reg. 221(5) omitted (31.12.2020 immediately before IP completion day) by virtue of The Human Medicines (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1488), reg. 1, Sch. 2 para. 180(c)

I1: Reg. 221 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1